Halobetasol/tazarotene (Duobrii) is a topical combination drug used to treat plaque psoriasis. It combines 0.01% halobetasol propionate (a corticosteroid that reduces inflammation and suppresses the immune system) and 0.045% tazarotene (a retinoid that promotes normal skin cell turnover and has anti-inflammatory effects) in a lotion formulation.[2][3][4][5] It was approved as a prescription drug by the U.S. Food and Drug Administration (FDA) in April 2019[2][3][4][5] and by Health Canada in June 2020.[6][7]
| Combination of | |
|---|---|
| Ulobetasol propionate | Corticosteroid |
| Tazarotene | Retinoid |
| Clinical data | |
| Trade names | Duobrii |
| AHFS/Drugs.com | Multum Consumer Information |
| Routes of administration | Topical |
| Legal status | |
| Legal status | |
References
Wikiwand in your browser!
Seamless Wikipedia browsing. On steroids.
Every time you click a link to Wikipedia, Wiktionary or Wikiquote in your browser's search results, it will show the modern Wikiwand interface.
Wikiwand extension is a five stars, simple, with minimum permission required to keep your browsing private, safe and transparent.
